Mendus announces positive survival data from Phase 2 ADVANCE II trial evaluating vididencel as maintenance therapy for AML at ASH 2023

What we doOur approachPipelineTechnologyPublications
About usExecutive ManagementBoard of DirectorsScientific Advisory Board
News & eventsPress releasesEventsInterviews
Investors
Careers

Back
Mendus announces positive survival data from Phase 2 ADVANCE II trial evaluating vididencel as maintenance therapy for AML at ASH 2023 
 7:30:00 PM

Keep reading
Mendus AB: REPORT FROM THE EXTRAORDINARY GENERAL MEETING OF MENDUS AB (PUBL) ON 13 DECEMBER 2023Read